Arrestin-3 Agonism at Dopamine D₃ Receptors Defines a Subclass of Second-Generation Antipsychotics That Promotes Drug Tolerance.

"ACKNOWLEDGMENTS AND DISCLOSURES This work was supported by the National Institute of Mental Health (Grant No. R01MH112729 [to JLW and KJB]). SS, EL, AH, KJB, and JLW were responsible for conceptualization; SS, EL, CMK, AH, KJB, and JLW were responsible for methodology; SS, EL, CMK, KJB, and JLW were responsible for formal analysis; SS, EL, CMK, AH, KJB, and JLW were responsible for investigation; SS was responsible for writing the original draft; SS, EL, AH, KJB, and JLW were responsible for reviewing and editing; and KJB and JLW were responsible for supervision, project administration, and funding acquisition. We thank Dr. Michael Roberts for help with image analysis, Drs. Matthew McGregor and Anna Lipkin for assistance with data analysis, Anirudh Gaur for guidance on in vitro experiments, Dr. Robert Lefkowitz for the arrestin-3 knockout mice, Chenyu Wang and Henry Kyoung for assistance with intraperitoneal injections, and members of the Bender and Whistler labs for critically assessing this work. KJB receives research funding from BioMarin Pharmaceuticals. The other authors report no biomedical financial interests or potential conflicts of interest."

"This work was supported by the National Institute of Mental Health (Grant No. R01MH112729 [to JLW and KJB])."